{
    "N/R/U": null,
    "Applicant": "Celgene Corporation, a Bristol-Myers Squibb Company",
    "BLA Number": "761136",
    "Proprietary Name": "Reblozyl",
    "Proper Name": "luspatercept-aamt",
    "BLA Type": "351(a)",
    "Strength": "75MG/VIAL",
    "Dosage Form": "For Injection",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "November 08, 2019",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2252",
    "Product Number": "002",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "August 28, 2030"
}